Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 receptor agonist for obesity in people living with HIV
ChiCTR2500106381Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of semaglutide in obesity, Overweight and human immunodeficiency virus infection (HIV), sponsored by First Hospital of China Medical University. Primary endpoints: Medical history and physical examination, BMI, waist circumference, hip circumference and 17 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
03
Conditions
obesityOverweighthuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ChiCTR2500106381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106381.